HIGHLIGHTS
- What: The aim was to achieve MRD negativity ( and amp;lt;10-5 ). The phase 3 KarMMa-3 trial focused on patients with RRMM who had previously undergone two to four treatment regimens, including IMiDs, PIs, and daratumumab, and were refractory to their last regimen. This study reported results from cohort A, which included patients who had not previously received BCMAdirected therapy, totaling 123 participants .
- Who: Serena Rocchi and collaborators from the Hematology Unit and Romagna Metropolitan Transplant Network-Ravenna, University of Bologna have published the paper: Multiple Myeloma: The Role of Autologous Stem Cell . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.